FXYD6: a novel therapeutic target toward hepatocellular carcinoma.
10.1007/s13238-014-0045-0
- Author:
Qian GAO
1
;
Xiongfei CHEN
;
Hongxia DUAN
;
Zhaoqing WANG
;
Jing FENG
;
Dongling YANG
;
Lina SONG
;
Ningxin ZHOU
;
Xiyun YAN
Author Information
1. Key Laboratory of Protein and Peptide Pharmaceuticals, CAS-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antibodies, Monoclonal;
pharmacology;
Antineoplastic Agents;
pharmacology;
Carcinoma, Hepatocellular;
drug therapy;
metabolism;
Cell Line, Tumor;
Cell Movement;
Cell Proliferation;
Female;
HEK293 Cells;
Humans;
Ion Channels;
antagonists & inhibitors;
metabolism;
Liver Neoplasms;
drug therapy;
metabolism;
Mice, Inbred BALB C;
Mice, Nude;
Sodium-Potassium-Exchanging ATPase;
metabolism;
Tumor Burden;
drug effects;
Xenograft Model Antitumor Assays
- From:
Protein & Cell
2014;5(7):532-543
- CountryChina
- Language:English
-
Abstract:
FXYD6, FXYD domain containing ion transport regulator 6, has been reported to affect the activity of Na(+)/K(+)-ATPase and be associated with mental diseases. Here, we demonstrate that FXYD6 is up-regulated in hepatocellular carcinoma (HCC) and enhances the migration and proliferation of HCC cells. Up-regulation of FXYD6 not only positively correlates with the increase of Na(+)/K(+)-ATPase but also coordinates with the activation of its downstream Src-ERK signaling pathway. More importantly, blocking FXYD6 by its functional antibody significantly inhibits the growth potential of the xenografted HCC tumors in mice, indicating that FXYD6 represents a potential therapeutic target toward HCC. Altogether, our results establish a critical role of FXYD6 in HCC progression and suggest that the therapy targeting FXYD6 can benefit the clinical treatment toward HCC patients.
